García-Chías, BFiguero Ruiz, ElenaCastelo-Fernández, BCebrián-Carretero, JLCerero Lapiedra, Rocío2025-01-282025-01-282019-01-24Prevalence of oral side effects of chemotherapy and its relationship with periodontal risk: a cross sectional study. García-Chías B, Figuero E, Castelo-Fernández B, Cebrián-Carretero JL, Cerero-Lapiedra R. Support Care Cancer. 2019 Sep;27(9):3479-3490. doi: 10.1007/s00520-019-4650-60941-435510.1007/s00520-019-4650-6https://hdl.handle.net/20.500.14352/116501Purpose: To determine the prevalence of professionally reported oral side effects of chemotherapy and the self-reported oral side effects and whether both prevalences could be related to the periodontal risk of the patients. Methods: A cross-sectional study with patients undergoing chemotherapy treatment was carried out. Demographic, oral hygiene habits, and cancer-related data were collected while the patient was receiving the chemotherapy infusion. Patient's oral status, measured according to the oral-assessment guide for patients in hospital environments, patient-related outcomes (PROMs), measured by a visual analogue scale, and patient's periodontal risk were analyzed using validated questionnaires. Data was reported in means and standard deviations (SD) in quantitative variables and in counts, prevalence, and 95% confidence intervals (CI) in qualitative variables. ANOVA test and chi-squared tests were used to compare oral side effects among different periodontal risk groups. Results: Three hundred sixty-nine patients were included in the study. The prevalence of professionally reported oral side effects was 86.99% (95% confidence interval CI 83.54%; 90.44%). The prevalence of self-reported oral side effects was 89.70% (95% CI 86.59; 92.82). The most common oral side effects were xerostomia (73.4%), dysgeusia (61.8%), and dry lips (54.2%). More oral alterations were found in patients with worse periodontal risk (p < 0.001). Conclusions: The prevalence of oral side effects (professional or self-reported) is higher than 85% in patients undergoing chemotherapy. This prevalence increases as the risk of developing periodontal disease does.engjournal article1433-7339https://doi.org/10.1007/s00520-019-4650-630675665https://link.springer.com/article/10.1007/s00520-019-4650-6https://pubmed.ncbi.nlm.nih.gov/30675665/open access616.314.17-008.1:615.28615.28:616.314.17-008.1ChemotherapyOral side effectsXerostomiaPeriodontal riskDysgeusiaOdontología (Odontología)PeriodonciaOncología3213.13 Ortodoncia-Estomatología3207.13 Oncología